NFKB1 and neoplasm: These data suggest that BCL6 inhibitors may be beneficial in enhancing NF-kB signaling and Th9 function, especially in response to chronic antigens and in tumor draining lymph nodes tumors where Th cell BCL6 expression is elevated (74, 75).